Enzalutamide-话题@MedSci

#Enzalutamide#

8篇内容 | 1410人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2177988, encodeId=b77821e798822, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a> <a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=Eur Urol Oncol：Enzalutamide对年龄小于 75 岁和大于 75 岁的转移激素敏感性前列腺癌患者的临床疗效： ARCHES事后分析 , objectType=article, longId=807372, objectId=a0d080e3720d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231229/1703819057666_1935437.jpg, objectUrl=/article/show_article.do?id=a0d080e3720d, replyNumber=0, likeNumber=77, createdTime=2023-12-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a0d080e3720d, moduleTitle=Eur Urol Oncol：Enzalutamide对年龄小于 75 岁和大于 75 岁的转移激素敏感性前列腺癌患者的临床疗效： ARCHES事后分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d080e3720d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2170533, encodeId=018f21e053327, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a> <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, objectTitle=Eur Urol Oncol：Pembrolizumab和Enzalutamide在已经使用醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的效果如何？, objectType=article, longId=801828, objectId=d50c801828b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231122/1700624702069_1935437.jpg, objectUrl=/article/show_article.do?id=d50c801828b3, replyNumber=0, likeNumber=70, createdTime=2023-11-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d50c801828b3, moduleTitle=Eur Urol Oncol：Pembrolizumab和Enzalutamide在已经使用醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50c801828b3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1539267, encodeId=c8d5153926edb, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准, objectType=article, longId=209089, objectId=845f2090899d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=845f2090899d, replyNumber=0, likeNumber=75, createdTime=2021-03-29, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=845f2090899d, moduleTitle=转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=845f2090899d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539266, encodeId=490215392667d, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, objectType=article, longId=208515, objectId=d0982085157d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0982085157d, replyNumber=0, likeNumber=73, createdTime=2021-03-18, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0982085157d, moduleTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0982085157d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539265, encodeId=3074153926517, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=Nat Commun：MAO抑制剂phenelzine和clorgyline能够逆转去势抵抗性前列腺癌中enzalutamide的抗性, objectType=article, longId=195968, objectId=7286195968f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7286195968f2, replyNumber=0, likeNumber=0, createdTime=2020-06-18, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7286195968f2, moduleTitle=Nat Commun：MAO抑制剂phenelzine和clorgyline能够逆转去势抵抗性前列腺癌中enzalutamide的抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7286195968f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539264, encodeId=a4f3153926448, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=JCO：Enzalutamide治疗雄激素受体表达三阴性乳腺癌, objectType=article, longId=128012, objectId=d8f5128012e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8f5128012e9, replyNumber=0, likeNumber=60, createdTime=2018-01-29, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8f5128012e9, moduleTitle=JCO：Enzalutamide治疗雄激素受体表达三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8f5128012e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539263, encodeId=a2ee153926381, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=CLIN CANCER RES：前列腺切除术前新辅助Enzalutamide治疗, objectType=article, longId=97945, objectId=3eb39e945b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb39e945b2, replyNumber=0, likeNumber=81, createdTime=2017-05-06, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb39e945b2, moduleTitle=CLIN CANCER RES：前列腺切除术前新辅助Enzalutamide治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb39e945b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539262, encodeId=fb2b1539262bd, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=招募患者：Enzalutamide用于非转移去势难治前列腺癌患者的安全有效性临床研究, objectType=article, longId=48419, objectId=abf84841932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf84841932, replyNumber=0, likeNumber=90, createdTime=2015-03-21, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf84841932, moduleTitle=招募患者：Enzalutamide用于非转移去势难治前列腺癌患者的安全有效性临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf84841932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539261, encodeId=e17f1539261a1, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=NEJM：药物enzalutamide可有效治疗前列腺癌, objectType=article, longId=9185, objectId=925b918582, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925b918582, replyNumber=0, likeNumber=73, createdTime=2012-08-23, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925b918582, moduleTitle=NEJM：药物enzalutamide可有效治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925b918582)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539260, encodeId=d602153926082, content=<a href='/topic/show?id=1d806834c1' target=_blank style='color:#2F92EE;'>#Enzalutamide#</a>, objectTitle=Medivation与Astellas提交前列腺癌药物enzalutamide新药申请, objectType=article, longId=6483, objectId=b67e648371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b67e648371, replyNumber=0, likeNumber=70, createdTime=2012-05-26, rootId=0, userName=bbwuyu_007, userId=ca1813130281, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b67e648371, moduleTitle=Medivation与Astellas提交前列腺癌药物enzalutamide新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b67e648371)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Enzalutamide

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #临床疗效# #Enzalutamide#

Eur Urol Oncol：Enzalutamide对年龄小于 75 岁和大于 75 岁的转移激素敏感性前列腺癌患者的临床疗效： ARCHES事后分析

2023-12-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #Enzalutamide# #Pembrolizumab#

Eur Urol Oncol：Pembrolizumab和Enzalutamide在已经使用醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的效果如何？

2023-11-23发表于上海

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准

2021-03-29

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验

2021-03-18

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

Nat Commun：MAO抑制剂phenelzine和clorgyline能够逆转去势抵抗性前列腺癌中enzalutamide的抗性

2020-06-18

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

JCO：Enzalutamide治疗雄激素受体表达三阴性乳腺癌

2018-01-29

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

CLIN CANCER RES：前列腺切除术前新辅助Enzalutamide治疗

2017-05-06

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

招募患者：Enzalutamide用于非转移去势难治前列腺癌患者的安全有效性临床研究

2015-03-21

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

NEJM：药物enzalutamide可有效治疗前列腺癌

2012-08-23

bbwuyu_007 (审核中...)

前往app查看评论内容

#Enzalutamide#

Medivation与Astellas提交前列腺癌药物enzalutamide新药申请

2012-05-26

科室
- - 订阅+
  - 更多科室
工具
服务